Related Experiment Videos
Interleukin-6 and prostate cancer progression
P C Smith1, A Hobisch, D L Lin
1Unit for Laboratory Animal Medicine, Institute of Gerontology and Connective Tissue Oncology Program, Room 5304 CCGCB, 1500 E. Medical Center Drive, University of Michigan, Ann Arbor, MI 48109-0940, USA.
Cytokine & Growth Factor Reviews
|April 20, 2001
Summary
Interleukin-6 (IL-6) promotes prostate cancer progression and resistance to chemotherapy. Targeting IL-6 may offer new therapeutic strategies for advanced prostate cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Prostate cancer initially relies on androgens but can become androgen-independent.
- Interleukin-6 (IL-6) is increasingly implicated in prostate cancer progression.
- Elevated serum IL-6 levels correlate with tumor burden and patient morbidity.
Purpose of the Study:
- To investigate the role of IL-6 in prostate cancer progression.
- To explore IL-6 as a potential therapeutic target in androgen-independent prostate cancer.
Main Methods:
- Correlating serum IL-6 levels with prostate tumor burden.
- Investigating prostate tissue as a source of IL-6 and its receptor.
- Evaluating IL-6's function as a growth factor in prostate cancer cell lines.
- Assessing the effect of anti-IL-6 antibody on chemotherapy sensitivity in vitro.
- Analyzing IL-6's impact on signal transduction pathways and androgen receptor activity.
Main Results:
- Serum IL-6 levels correlate with prostate tumor burden and patient morbidity.
- Prostate tissue is a source of IL-6 and its receptor.
- IL-6 acts as an autocrine and paracrine growth factor for androgen-independent prostate cancer cells.
- Anti-IL-6 antibody treatment sensitizes these cells to chemotherapy in vitro.
- IL-6 activates signaling cascades that can enhance androgen receptor activity.
Conclusions:
- IL-6 plays a significant role in the progression of prostate cancer, particularly in the androgen-independent state.
- Targeting IL-6 presents a promising therapeutic strategy with potential to improve treatment outcomes for prostate cancer patients.
- IL-6's multifaceted actions, including growth factor activity and influence on androgen receptor signaling, highlight its importance in prostate cancer pathogenesis.